Why Not All Thyroid Cancers Need Aggressive Treatment
Not all thyroid cancers behave the same. Modern care is personalized—the goal is to treat what matters while avoiding unnecessary treatment.
🧠 The key concept: Risk-adapted management
Many thyroid cancers—especially low-risk papillary thyroid cancers—are:
Slow-growing Unlikely to spread Associated with excellent long-term survival
Because of this, more treatment is not always better.
⚖️ Treatment options today
Depending on risk, options may include:
Active surveillance (careful ultrasound follow-up, no immediate surgery) Thyroid lobectomy instead of total thyroidectomy Selective use of radioactive iodine (not routine for everyone)
➡️ These approaches are evidence-based and safe for appropriately selected patients.
📉 Why avoid overtreatment?
Unnecessary aggressive treatment can:
Increase risk of hypocalcemia and voice changes Require lifelong thyroid hormone replacement Affect quality of life without improving outcomes
🦋 What matters most
Treatment decisions should be guided by:
✔️ Tumor size and ultrasound features
✔️ Pathology and risk of recurrence
✔️ Patient age, preferences, and values
✔️ Expertise of a multidisciplinary thyroid team
👨⚕️ Dr. Rodrigo Arrangoiz, MD
Surgical Oncologist – Thyroid, Head & Neck, Breast
Mount Sinai Medical Center
📌 Take-home message:
The best thyroid cancer treatment is the right treatment for the right patient—not the most aggressive one.
📚 References
Haugen BR et al. ATA Guidelines for Differentiated Thyroid Cancer. Thyroid Tuttle RM et al. Active surveillance for low-risk papillary thyroid cancer. JAMA Brito JP et al. Overdiagnosis and overtreatment of thyroid cancer. BMJ
Lobectomy may be considered in select patients with sporadic medullary thyroid cancer (MTC), though total thyroidectomy with central neck dissection remains the standard of care. The evidence base is evolving, with growing data supporting comparable oncologic outcomes for carefully selected patients.
Guideline Recommendations
The NCCN Thyroid Carcinoma Guidelines (v2.2026) recommend total thyroidectomy with central neck dissection (level VI) as the standard primary treatment for MTC. However, the guidelines now explicitly state that “lobectomy can be considered in select cases without RET pathogenic variant if no concerns for contralateral nodules.” This represents a notable shift toward acknowledging lobectomy as an option.
For MTC diagnosed after initial thyroid surgery (e.g., lobectomy), the NCCN notes that completion thyroidectomy may not be necessary unless there is a positive germline RET pathogenic variant or radiographic evidence of disease (biopsy-proven residual neck disease).
The ATA Guidelines similarly state that completion thyroidectomy following hemithyroidectomy is not indicated unless the patient has a RET germline mutation, significant postoperative calcitonin elevation, or imaging showing residual MTC. In a prospective study of 15 patients with sporadic MTC treated by hemithyroidectomy, 80% achieved biochemical cure.
Hereditary MTC (MEN2A/MEN2B) remains a strict indication for total thyroidectomy, as the likelihood of bilateral disease approaches 100%.
Key Evidence Supporting Lobectomy in Sporadic MTC
A 2026 systematic review and meta-analysis in JAMA Otolaryngology (9 studies, 1,371 patients) found that lobectomy was associated with comparable oncologic outcomes to total thyroidectomy in selected patients with sporadic MTC:
– Mortality: No difference at 5 years (RR 0.30; 95% CI 0.07–1.35) or beyond (RR 1.00; 95% CI 0.40–2.47)
– Overall survival at 5 years: Similar (RR 1.02; 95% CI 0.94–1.11)
– Biochemical cure: No difference at 5 or beyond 5 years
– Structural recurrence at 5 years: No difference (OR 0.45; 95% CI 0.14–1.49), though total thyroidectomy was associated with lower recurrence beyond 5 years (OR 7.26; 95% CI 1.07–49.21) — a finding with very wide confidence intervals
– Postoperative complications: More common with total thyroidectomy
Multiple SEER-based analyses corroborate these findings:
– A propensity-matched study (122 pairs, median follow-up 99 months) showed no significant difference in 10-year overall survival (85.2% vs. 83.1%) or disease-specific survival between total thyroidectomy and lobectomy for localized MTC.
– Another SEER analysis of T1N0/1M0 MTC (398 patients, median follow-up 8.75 years) found no survival difference between approaches (cancer-specific mortality HR 0.44, p = 0.23).
– A 2025 SEER analysis with Chinese cohort validation confirmed no survival difference and demonstrated significantly more adverse events with total thyroidectomy, including transient hypocalcemia (p < 0.001) and vocal cord paralysis (p < 0.025).
Occult Contralateral Disease
A key concern with lobectomy is missing contralateral foci. A multi-institutional JAMA Otolaryngology study found that the prevalence of sonographically occult contralateral disease in sporadic MTC was only 5.0%, with a 95.7% reduction in odds compared to germline disease (adjusted OR 0.034). Among patients who underwent lobectomy alone, 41.7% achieved undetectable calcitonin levels. A 2026 European study found zero cases of occult contralateral disease in 48 patients with sporadic MTC when high-quality preoperative ultrasound was available.
Patient Selection Criteria for Lobectomy
Based on the available evidence, lobectomy with ipsilateral central neck dissection may be appropriate when all of the following are met:
– Sporadic disease (no germline RET pathogenic variant)
– Unifocal tumor confined to one lobe with no contralateral nodules on ultrasound
– Clinically node-negative (cN0) with preoperative calcitonin ≤250 pg/mL
– No extrathyroidal extension
– Tumor size <2 cm (most studied population)
– Absence of desmoplastic stroma reaction on intraoperative frozen section (if available)
—Important Caveats
Important Caveats
All existing data are retrospective, with inherent selection bias — patients who underwent lobectomy likely had lower-risk disease. The meta-analysis signal of potentially higher structural recurrence beyond 5 years with lobectomy warrants attention, though confidence intervals were very wide. Calcitonin surveillance is more complex after lobectomy, as residual normal C cells may produce low-level calcitonin, complicating interpretation. Prospective randomized trials are needed to definitively establish the safety of lobectomy in this setting.
Key References
– Lincango EP et al. Total Thyroidectomy vs Lobectomy for Sporadic Medullary Thyroid Cancer: A Systematic Review and Meta-Analysis. JAMA Otolaryngol Head Neck Surg. 2026.
– Mao YV et al. Extent of Surgery for Medullary Thyroid Cancer and Prevalence of Occult Contralateral Foci. JAMA Otolaryngol Head Neck Surg. 2024.
– Wells SA et al. Revised American Thyroid Association Guidelines for the Management of Medullary Thyroid Carcinoma. Thyroid. 2015.
– Liang W et al. Total Thyroidectomy vs Thyroid Lobectomy for Localized Medullary Thyroid Cancer in Adults: A Propensity-Matched Survival Analysis. Surgery. 2022.
– Yang J et al. Comparison of Lobectomy vs Total Thyroidectomy for Medullary Thyroid Carcinoma: A SEER Analysis With Chinese Cohort Validation. Oncologist. 2025.
– Spörlein A et al. Is Hemithyroidectomy Enough? Low Risk of Occult Contralateral Disease in Sporadic Medullary Thyroid Cancer. Eur Arch Otorhinolaryngol. 2026.
– Park H et al. Preoperative Identification of Low-Risk Medullary Thyroid Carcinoma: Potential Application to Reduce Total Thyroidectomy. Sci Rep. 2023.
A painless neck mass (metastatic cervical lymphadenopathy) and sore throat:
Are the two most common presenting features of oropharyngeal squamous cell carcinoma (OPSCC):
But the pattern differs strongly by HPV status:
HPV-associated tumors (tonsil, base of tongue) frequently present with an asymptomatic or occult primary and a cervical neck mass
HPV-negative tumors more often produce local symptoms from the primary site such as sore throat, dysphagia, and odynophagia:
Because these symptoms overlap with benign conditions (reflux, globus, branchial cleft cyst), any persistent neck mass or throat symptom in an adult should be considered malignant until proven otherwise
Most common presenting symptoms / signs:
Neck mass (cervical lymphadenopathy):
The single most frequent initial complaint (~ 44% to 52%):
Typically a new, painless, often cystic level II node:
Commonly the first and only sign of an HPV-associated primary
Sore throat:
Persistent, often unilateral (~ 33%)
Dysphagia:
Difficulty swallowing
Odynophagia:
Pain on swallowing
Otalgia:
Referred ear pain via the glossopharyngeal /vagal pathways:
Especially with tonsil and base-of-tongue lesions
Globus sensation:
Feeling of a mass or fullness in the throat
Visualized oropharyngeal mass or tonsillar asymmetry / ulceration
Less common / advanced-disease features:
Voice change / muffled (“hot potato”) voice
Hemoptysis or blood-tinged saliva
Unintentional weight loss
Trismus and impaired tongue mobility / dysarthria:
Reflecting deep muscular or hypoglossal nerve involvement (base of tongue), often signaling locally advanced disease
Otalgia with a normal otologic exam:
Should specifically prompt oropharyngeal evaluation
HPV-positive vs HPV-negative presentation:
This distinction is clinically important because it drives suspicion in patients lacking traditional tobacco / alcohol risk factors
Clinical caveats:
HPV-associated cystic nodal metastases are frequently mistaken for benign cysts:
The prevalence of malignancy in a cystic neck mass in patients > 40 years is approximately 80%:
So FNA (ideally image-guided) is warranted rather than observation
Anatomically hidden oropharyngeal primaries become symptomatic late, so absence of a visible lesion does not exclude malignancy:
Nasolaryngoscopy and cross-sectional imaging are indicated for persistent symptoms
OPSCC is a leading cause of carcinoma of unknown primary:
p16 / HPV testing of nodal tissue helps localize the oropharynx as the source
References:
Dunn LA, Ho AL, Pfister DG. Head and Neck Cancer. JAMA. 2025.
McIlwain WR, Sood AJ, Nguyen SA, Day TA. Initial Symptoms in Patients With HPV-Positive and HPV-Negative Oropharyngeal Cancer. JAMA Otolaryngol Head Neck Surg. 2014.
Johnson DE, Burtness B, Leemans CR, et al. Head and neck squamous cell carcinoma. Nat Rev Dis Primers. 2020.
Lechner M, Liu J, Masterson L, Fenton TR. HPV-associated oropharyngeal cancer: epidemiology, molecular biology and clinical management. Nat Rev Clin Oncol. 2022.
Wilbur J, Tran VL, Doobay MF. Evaluation of Neck Masses in Adults. Am Fam Physician. 2026. Dunn LA, Ho AL, Pfister DG. Head and Neck Cancer. JAMA. 2025.
Khalid MB, Ting P, Pai A, et al. Initial Presentation of Human Papillomavirus-Related Head and Neck Cancer: A Retrospective Review. Laryngoscope. 2019.
McIlwain WR, Sood AJ, Nguyen SA, Day TA. Initial Symptoms in Patients With HPV-Positive and HPV-Negative Oropharyngeal Cancer. JAMA Otolaryngol Head Neck Surg. 2014.
Lawless AK, Duruchukwu E, Bergamin S, et al. De-Escalation of Radiotherapy in the Treatment of Human Papillomavirus-Associated Oropharyngeal Cancer. Cochrane Database Syst Rev. 2025.
McIlwain WR, Sood AJ, Nguyen SA, Day TA. Initial Symptoms in Patients With HPV-Positive and HPV-Negative Oropharyngeal Cancer. JAMA Otolaryngol Head Neck Surg. 2014.
Johnson DE, Burtness B, Leemans CR, et al. Head and neck squamous cell carcinoma. Nat Rev Dis Primers. 2020.
Jerjes W, Upile T, Hamdoon Z, et al. Photodynamic therapy: The minimally invasive surgical intervention for advanced and/or recurrent tongue base carcinoma. Lasers Surg Med. 2011.
Wilbur J, Tran VL, Doobay MF. Evaluation of Neck Masses in Adults. Am Fam Physician. 2026.
Amin JD, Rodriggs T, Weir KA, Snider JW, Hatten KM. Prospective Evaluation of Swallowing Symptoms in Human Papillomavirus-Associated Oropharynx Cancer. Dysphagia. 2022.
Dunn LA, Ho AL, Pfister DG. Head and Neck Cancer. JAMA. 2025.
A totally implantable venous access port (TIVAP / port-a-cath) provides reliable long-term central venous access for chemotherapy, parenteral nutrition, blood products, and antibiotics. Overall reported complication rates range from about 2% to 14.4%, and are broadly lower with ultrasound-guided internal jugular vein (IJV) access and standardized protocols (Tabatabaie et al., American Journal of Clinical Oncology, 2017; Camargo et al., Scientific Reports, 2026). Complications are grouped by timing (intraoperative/immediate, early ≤30 days, late >30 days) and by anatomic origin (incision/pocket, catheter, reservoir/port).
Complication Categories and Reported Incidence
Complication Timing Reported incidence Key management Pneumothorax Intraoperative ~0.5–6% (higher with subclavian/landmark technique; ~0 with US + IJV) Observation vs. chest tube depending on size; US guidance largely eliminates risk Hemothorax Intraoperative Rare Drainage/chest tube; vascular repair if arterial laceration Arterial puncture (carotid ~3%, subclavian rarer) Intraoperative ~3% carotid Manual compression; vascular surgery if large-vessel injury Air embolism Intraoperative Rare Trendelenburg/left lateral position, 100% O2, aspiration Cardiac arrhythmia (guidewire/tip) Intraoperative Up to ~9% with tip migration Withdraw guidewire/reposition tip to cavoatrial junction Catheter malposition Early ~0.3% Fluoroscopic/endovascular repositioning (pigtail, gooseneck snare) Hematoma / pocket bleeding Early Low (minor) Compression; evacuation if expanding Wound dehiscence / skin erosion / port extrusion Early–late ~0.6% extrusion Wound care; often requires revision/explantation Infection (pocket, tunnel, exit site, CRBSI) Early–late (most common) ~1.5–5% pocket/site; CRBSI ~0.05–0.9/1000 catheter-days Systemic antibiotics ± antibiotic lock; removal for complicated infection Catheter-related thrombosis / venous stenosis Late Thrombosis ~0.3–28% (series-dependent); venous stenosis ~7% Anticoagulation; thrombolysis or removal in severe cases Catheter occlusion / fibrin sheath Late Variable Thrombolytic instillation (e.g., alteplase); fibrin sheath stripping Catheter fracture / disconnection / embolization Late Rare Endovascular retrieval; surgical revision Port flip / rotation Late Rare (single cases) Manual or surgical repositioning Extravasation Late Rare Stop infusion, aspirate, antidote per agent, surgical consult
Timing Patterns from Recent Cohorts
Standardized US-guided IJV series (n=175): 100% procedural success, no early complications, 8.0% late complications (all skin ulceration around port/catheter). Concurrent diabetes + hypertension was the only independent risk factor (HR 12.2) (Ma et al., The American Surgeon, 2026).
>1000 TIVAP series: No intraoperative/perioperative complications; 12% total complications (26.7% early, 73.3% late). Most common were infection (4.7%) and thrombosis (3.6%). Infectious complications carried the highest explantation rates; thrombotic complications were usually managed conservatively (Thiel et al., Langenbeck’s Archives of Surgery, 2022).
Large oncology cohort (n=1180): 100% technical success; early events mostly minor (pain 24.7%, bruising 9.2%). Late: site cellulitis 3.8%, CRBSI 0.25%, thrombosis 0.25%, port extrusion 0.6% (Tashi et al., Annals of the Academy of Medicine, Singapore, 2024).
Vascular surgeon image-guided series (n=443): No intraoperative/early complications; 2.0% late (infection, thrombosis, erosion, malfunction) (Kim, Journal of Surgical Research, 2025).
Infection is both the most frequent and earliest category, with a steep early rise; catheter- and port-related events accrue more gradually (Tsuruta et al., Supportive Care in Cancer, 2020).
Management Principles
Infection
Systemic antimicrobial therapy is the treatment of choice; device removal is required for complicated infection (tunnel/pocket infection, severe sepsis/septic shock, endocarditis, septic thrombophlebitis, osteomyelitis, hematogenous seeding).
Infections due to S. aureus or Candida spp. generally warrant removal. Uncomplicated CRBSI not caused by these organisms may be treated conservatively with systemic antibiotics + antibiotic lock therapy.
Remove if blood cultures remain positive 72 h after starting antibiotics (Lebeaux et al., The Lancet Infectious Diseases, 2014).
Most guidelines cite ~0.3 infections/1000 catheter-days as an acceptable upper threshold (Walser, Cardiovascular and Interventional Radiology, 2012).
Thrombosis / occlusion
Mechanical occlusions need cause-specific treatment; thrombotic occlusions usually resolve with thrombolytic instillation (e.g., alteplase).
Catheter-related thrombosis: anticoagulation for ~6 weeks to a year depending on extent and persistence of risk factors; balance against bleeding/coagulopathy risk. Anticoagulation prophylaxis is not routinely recommended (Baskin et al., Lancet, 2009).
Preventive measures: correct tip positioning at the cavoatrial junction and infection prevention.
Mechanical (fracture, migration, port flip)
Endovascular retrieval/repositioning (pigtail catheter, gooseneck snare) under fluoroscopy; surgical revision or replacement for breakage or port separation (Wang et al., Current Medical Research and Opinion, 2025).
Local skin/pocket problems
Port repositioning to a new pocket may salvage the device in selected local infections, avoiding full re-implantation (Sun et al., European Journal of Medical Research, 2025).
Prevention
Ultrasound-guided venous puncture and fluoroscopic tip confirmation reduce pneumothorax, arterial injury, and malposition.
Right IJV access is associated with lower rates of malposition, thrombosis, and pneumothorax than subclavian access.
Operator experience matters: complication likelihood is roughly halved for operators with ≥50 insertions.
Strict sterile access technique and standardized maintenance/locking protocols reduce CLABSI and occlusion.
In this comprehensive review, Fernando Cordera and I examine the evolving management of oral cavity squamous cell carcinoma (OCSCC), a disease in which surgery remains the cornerstone of treatment, but where optimal outcomes increasingly depend on precise risk stratification and coordinated multidisciplinary care.
Several important concepts emerge from the contemporary evidence:
🔹 Depth of invasion (DOI) matters. DOI has become a critical prognostic variable in oral cavity SCC, influencing T classification, the risk of occult cervical nodal metastasis, and decisions regarding management of the clinically N0 neck.
🔹 The neck must be addressed appropriately. Elective neck treatment remains a fundamental component of management for patients at meaningful risk of occult nodal disease. Sentinel lymph node biopsy is also emerging as an effective alternative to elective neck dissection in appropriately selected early-stage patients and experienced centers.
🔹 Pathology drives postoperative treatment. Margin status, nodal burden, extranodal extension, perineural invasion, lymphovascular invasion, and DOI are central to postoperative risk stratification and decisions regarding adjuvant radiation or chemoradiation.
🔹 Surgery is evolving toward oncologic control with functional preservation. Achieving adequate oncologic resection remains paramount, but contemporary treatment must simultaneously consider speech, swallowing, reconstruction, appearance, and long-term quality of life.
🔹 Immunotherapy is changing the treatment landscape. The KEYNOTE-689 trial represents an important shift in the management of selected patients with locally advanced, resectable head and neck squamous cell carcinoma, demonstrating improved event-free survival with the integration of perioperative pembrolizumab into standard treatment.
Perhaps the most important message is that oral cavity cancer can no longer be approached as surgery alone. Optimal care requires integration of head and neck surgical oncology, reconstructive surgery, radiation oncology, medical oncology, pathology, radiology, dentistry, speech and swallowing rehabilitation, nutrition, psychosocial support, and survivorship care.
Our goal with this review was to bring together the contemporary evidence—from epidemiology, anatomy and staging to surgical management, neck dissection, reconstruction, adjuvant therapy, immunotherapy, surveillance, recurrence, and survivorship—into a practical framework for clinicians treating patients with oral cavity cancer.
Reference: Arrangoiz R, Cordera F. Oral Cavity Squamous Cell Carcinoma: Contemporary Evidence-Based Management and Multidisciplinary Care. JSM Head Neck Cancer Cases Rev. 2026;6(1):1013.
An important new analysis from the NRG Oncology/NSABP B-35 randomized clinical trial, published in JAMA Surgery, challenges how rigidly we should apply margin-width thresholds in selected patients with ductal carcinoma in situ (DCIS).
Wapnir and colleagues evaluated the association between lumpectomy margin width and ipsilateral breast tumor recurrence (IBTR) among 3,104 postmenopausal women with hormone receptor–positive DCIS enrolled in NSABP B-35. All patients underwent breast-conserving surgery followed by whole-breast irradiation (WBI) and received 5 years of endocrine therapy with either tamoxifen or anastrozole. (JAMA Network)
🔹 What did the study find?
Using a 1-mm threshold, the 10-year cumulative incidence of IBTR was:
Although these differences were statistically significant or borderline significant on unadjusted analysis, the absolute differences were small—approximately 1.5–1.6% at 10 years. (JAMA Network)
More importantly, after adjustment for patient and tumor characteristics, margin width was no longer a significant independent predictor of ipsilateral recurrence. For the 2-mm threshold, the adjusted HR was 1.33 (95% CI, 0.86–2.06). (JAMA Network)
🔹 Why is this important?
Current SSO-ASTRO-ASCO consensus guidance has established 2 mm as the standard adequate margin for DCIS treated with breast-conserving surgery and WBI. However, the guideline already emphasizes that a negative margin <2 mm does not automatically mandate additional surgery and that clinical judgment should guide re-excision decisions. (ASCO Publications)
The B-35 data strengthen that concept.
For an appropriately selected postmenopausal patient with HR-positive DCIS, a negative but close margin should not necessarily trigger an automatic return to the operating room when the patient will receive whole-breast radiation and endocrine therapy.
The decision should incorporate the entire clinical picture: extent of DCIS near the margin, residual calcifications, which margin is close, patient age and comorbidities, anticipated radiation and endocrine therapy, and the potential cosmetic and morbidity consequences of another operation. (ASCO Publications)
My takeaway: The goal of DCIS surgery should remain oncologically sound excision, but margin width should be interpreted as part of the overall treatment strategy rather than as an isolated number.
A 2-mm margin remains an important benchmark, but these prospective trial data support a more individualized approach to re-excision—particularly when the margin is negative and effective adjuvant therapy is planned.
Importantly, these findings should not be generalized to all patients with DCIS. The B-35 population consisted specifically of postmenopausal women with HR-positive DCIS receiving both WBI and endocrine therapy. (JAMA Network)
References
Wapnir IL, Cecchini RS, Dignam JJ, et al. Lumpectomy Margins and Local Recurrence in DCIS: Results From the NRG Oncology/NSABP B-35 Randomized Clinical Trial. JAMA Surg. 2026;161(9):861-869. doi:10.1001/jamasurg.2026.2340. (JAMA Network)
Morrow M, Van Zee KJ, Solin LJ, et al. Society of Surgical Oncology–American Society for Radiation Oncology–American Society of Clinical Oncology Consensus Guideline on Margins for Breast-Conserving Surgery With Whole-Breast Irradiation in Ductal Carcinoma In Situ. J Clin Oncol. 2016;34(33):4040-4046. (ASCO Publications)
Morrow M, Abrahamse P, Hofer TP, et al. Lumpectomy Margins for Invasive Breast Cancer and Ductal Carcinoma in Situ: Current Guideline Recommendations, Their Implications, and Impact. J Clin Oncol. 2020. (ASCO Publications)
Understanding the genetic mutations associated with thyroid cancer has become increasingly important. The most common genetic mutations found in thyroid cancer include BRAF, RAS, RET/PTC, and PAX8/PPARγ. These mutations can provide valuable information for diagnosis, prognosis, and targeted treatment approaches.
Molecular testing, such as next-generation sequencing (NGS), has gained prominence in thyroid cancer diagnosis and management. It allows for the identification of specific genetic alterations and can guide treatment decisions. Testing for specific genetic mutations, such as BRAF V600E, may help determine the use of targeted therapies like BRAF inhibitors.
Advances in understanding the molecular alterations in thyroid cancer have led to the development of targeted therapies. Tyrosine kinase inhibitors (TKIs) have shown promise in treating advanced or metastatic thyroid cancer, particularly those with RET rearrangements, BRAF mutations, or vascular endothelial growth factor receptor (VEGFR) mutations.
Immune checkpoint inhibitors, such as pembrolizumab and nivolumab, have shown effectiveness in a subset of patients with advanced or refractory thyroid cancer. These therapies work by unleashing the immune system to target cancer cells. However, response rates can vary, and not all patients will benefit from immunotherapy.
Molecular testing can help refine risk stratification in thyroid cancer. Genetic profiling of the tumor can aid in distinguishing low-risk from high-risk thyroid cancers, allowing for tailored treatment plans and surveillance strategies.
Both split-thickness (STSG) and full-thickness (FTSG) skin grafts are avascular free tissue transfers that heal through the same three sequential phases. They differ in the speed/reliability of that process and in the trade-offs (contraction, durability, cosmesis, donor-site burden) that drive graft selection.
Shared Healing Sequence
Plasmatic imbibition (~first 24–48 hrs): The graft has no vascular connection to the bed and survives by passive diffusion of oxygen and metabolites from plasma exudate. Fibrin secures the graft. Close apposition and immobilization are critical; thinner grafts tolerate this ischemic period better.
Inosculation (~day 2–4 onward): A capillary network proliferates and anastomoses form between preexisting graft vessels and recipient-bed vessels, restoring continuity and giving the graft a pink color.
Revascularization/angiogenesis (~day 3–7, maturing through ~day 10–12): New vessels grow in from the wound bed while native graft vasculature regresses and is replaced. Ingrowth of recipient vasculature predominates. Afferent/efferent flow is generally restored by roughly days 8–12, though perfusion continues to evolve for weeks.
Why Thickness Affects Healing
STSG (epidermis + partial dermis): Thinner, lower metabolic demand, revascularizes faster and more reliably — “takes” more readily on marginal or larger beds.
FTSG (epidermis + full dermis): More tissue to perfuse across the same diffusion distance, higher metabolic demand — requires a well-vascularized bed and meticulous immobilization.
Indications: When to Use Each
Factor STSG FTSG Best for Large wounds, burns, marginal/less vascular beds, temporary coverage Small wounds needing durable, cosmetically superior coverage Graft take More reliable Less forgiving; needs excellent bed Secondary contraction Greater (more wound contraction) Minimal — preferred over joints, hands, face Cosmesis / color match Poorer, can be shiny/dyschromic Superior; better texture and pigment match Durability Less durable More durable, better sensation return Donor site Heals spontaneously; can re-harvest Must be closed primarily; limits size Typical sites Trunk, extremities, burns Face (nose, eyelids, ear), fingertips, palmar surfaces
Practical Selection Summary
Choose STSG when the priority is reliable coverage of a large area or a suboptimal bed.
Choose FTSG when the priority is cosmesis, durability, and minimizing contraction in a small wound at a functionally or cosmetically sensitive site with a well-vascularized bed.
Numerous histologic variants of PTC have been described based on architectural or cellular features
Acknowledgement of the tumor subtype is important:
As it can contribute to the risk stratification of individual tumors
The classic subtype of PTC and the follicular subtype of PTC (FVPTC) are associated with very favorable outcomes
More concerning histologic subtypes include:
Tall cell, hobnail subtype, and, perhaps to a lesser extent, columnar cell:
These tumors tend to present at an older age and with more advanced disease than is seen in classic PTC
These more aggressive histologic subtypes:
Also are associated with worse recurrence-free and disease-specific survival rates
Tumor Size
Primary tumor size is closely associated with the outcome of PTC, including both 10-year recurrence and cancer-specific mortality rates
Cancer-specific mortality rates increase incrementally from 2% for tumors 8 cm
Furthermore, larger tumors are associated with a higher rate of locoregional and distant metastases
Multifocality
Patients with PTC have a 32% to 45% chance of cancer elsewhere in the ipsilateral or contralateral lobe
Tumor multifocality is also found frequently in papillary thyroid microcarcinomas (PMCs)
Multifocal disease increases the risk of recurrence, particularly in patients who have had a lobectomy
With the current trend to performing lobectomy for the majority of low-risk cancers, some have raised concerns about the potential for increased recurrence rates
Indeed, some patients may develop recurrence in the remaining contralateral lobe, necessitating completion thyroidectomy at a later date:
Fortunately, it is the minority (7% at 10 years of follow-up) of patients who will require such an intervention
A large, long-term follow-up study of patients undergoing lobectomy for PTC:
14.6% of whom had multifocal disease, demonstrated a recurrence-free 20-year survival rate of 95% in the opposite lobe, 91% for lymph node (LN) recurrence, and a disease-specific survival rate of 97.8%
Predictors of recurrence or worse disease-specific survival were:
Age
Primary tumor > 4 cm
Clinically apparent LNs
Suggesting that properly selected patients will have an excellent prognosis after lobectomy of PTC
The implications of tumor multifocality on survival are controversial:
Some studies have determined that multifocal disease does not increase the risk of disease-specific mortality
However, when distinguishing unilateral multifocal from bilateral disease, other studies have demonstrated that survival was lower for bilateral tumors
Extrathyroidal Extension
Extrathyroidal extension (ETE) of tumor beyond the thyroid capsule into the perithyroidal soft tissues and adjacent structures:
May be seen in up to 40% of surgical specimens and is an important prognostic factor in PTC
The specific extent of ETE should be described on the surgical pathology report
Minimal ETE is defined as:
Microscopic visualization of tumor into the immediate perithyroidal soft tissues
In contrast, extensive ETE is described as:
Gross tumor extension into subcutaneous soft tissues, larynx, trachea, esophagus, or the recurrent laryngeal nerve (RLN)
The prognostic implications of ETE in differentiated thyroid cancer is controversial, which may stem largely from a failure to distinguish between these distinct degrees of tumor spread
It is generally accepted that tumor extension into the surrounding tissues:
Which is visible intraoperatively or on preoperative imaging:
Is associated with a worse prognosis
The implications of minimal ETE on outcomes, however, is less clear:
Some retrospective studies have demonstrated that minimal ETE is associated with higher rates of LN metastases
Other studies found recurrence rates in those with minimal ETE were dependent on primary tumor size
In contrast others have found that minimal ETE is not associated with increased recurrence or decreased survival
A recent systematic review and meta-analysis of the effects of minimal ETE on survival and recurrence demonstrated:
No influence of minimal ETE on disease-related mortality but did indicate an increased risk of recurrence in patients with minimal ETE
The absolute recurrence risk increase for patients with lymph node negative disease was from 2.2% to 3.5% and for patients with lymph node positive disease the increase was from 6.2% to 7%:
Suggesting that the effects of minimal ETE on absolute risk for disease recurrence was small
Indeed, the 8th edition of The American Joint Committee on Cancer/The Tumor, Node, and Metastases (AJCC/TNM) cancer staging system removed the minimal ETE definition and its influence on overall tumor stage
This omission is an acknowledgment of the negligible effects of minimal ETE on tumor-associated mortality
Lymph Node Metastases
The incidence rates of cervical LN metastases identified at the time of initial surgery in patients with PTC varies widely, depending on the mode of nodal detection
Prophylactic LN dissections yield high rates of LN micrometastases (up to 65%)
Whereas gross nodal involvement detected by preoperative US or during surgery occurs in a smaller, but still substantial, percentage (20%) of patients
The manner of discovery is important as it is related to the prognostic significance of nodal involvement:
Those nodes incidentally identified on surgical pathology with microscopic tumor deposits:
Do not significantly alter risk of recurrence
Prophylactic nodal dissection, therefore, is not recommended as it does not lower recurrence-free survival and risks upstaging patients:
Resulting in unnecessary additional treatment
In contrast, grossly abnormal nodes:
Are associated with a worse recurrence-free survival:
Removal of these nodes is thus considered therapeutic
The number of involved nodes:
Is also related to the recurrence risk
Even with microscopic nodal deposits:
More than five involved nodes:
Carries a higher risk of recurrence compared with lower numbers of diseased nodes:
7% to 21% and 3% to 8%
The effects of LN metastases on survival is less clear:
There are conflicting reports regarding cancer-specific mortality in the presence of nodal involvement
An analysis of the Surveillance, Epidemiology, and End Results (SEER) database:
Determined that nodal metastases were associated with increased mortality only in those patients over the age of 45 years:
However, a more recent study of patients from the SEER database and the National Cancer Database (NCDB) of patients under the age of 45 years:
Found that increasing numbers of nodal metastases were associated with decreasing overall survival up to six nodes, after which more metastatic nodes conferred no additional mortality risk
Distant Metastases
Although distant metastases are uncommon in PTC:
They are present in approximately 5% of patients at the time of initial diagnosis:
Another 2.5% to 5% will develop distant metastases after initial therapy
The most common sites of involvement are:
Lung (50%) and bone (25%):
Followed by both lung and bone (20%) and other tumor sites (5%)
One study found a 50% survival rate of 3.5 years:
However, subsets of patients have better survival rates, especially postpubertal children, those with microscopic metastases, and patients with iodine-avid tumors
Additional prognostic information about distant metastases may be gained by performing 2-[18F]fluoro-2-deoxy-D- glucose-positron emission tomography (18FDG-PET) /computed tomography (CT) scanning:
One study found an inverse relationship between survival and degree of 18FDG-PET avidity of the most active lesion as well as the number of (18FDG-PET)–avid lesions
Patients with a positive 18FDG-PET scan had a 7.28-fold increased risk of dying from thyroid cancer compared with patients who had a negative scan
Oncogenes
The MAPK (mitogen-activated protein kinase) pathway:
Is an intracellular signaling cascade that results in:
Cell growth
Proliferation
Apoptosis
A mutation in one of these signaling components in the MAPK pathway is responsible for the majority of PTCs:
These mutations are almost always mutually exclusive:
Suggesting that a single molecular alteration is sufficient to drive oncogenesis
Detection of these mutations may be used to:
Identify malignancy on fine-needle aspiration (FNA)
To prognosticate for patients with thyroid cancer
To guide the systemic agent used in radioiodine-refractory disease
BRAF
BRAF is a serine / threonine kinase in the MAPK signaling pathway:
That regulates cellular differentiation, proliferation, and survival
The independent prognostic utility of a BRAF mutation remains in question, however
With such a high prevalence of this pathogenic variant and the excellent outcomes in the majority of thyroid cancer patients, the specificity of BRAF for prognostication is limited:
Further, because BRAF is often associated with high-risk clinical features, it is difficult to discern what component of the poor outcomes seen with this pathogenic variant are due to the mutation itself, independent of the pathologic elements
Indeed several studies attempting to determine whether BRAF serves as an independent predictor of recurrence have produced mixed results
The identification of a BRAF mutation instead may provide:
Direction for the management of radioiodine refractory tumors:
A recent clinical trial aimed at redifferentiating noniodine-avid tumors:
Used a BRAF-inhibitor, dabrafenib:
60% of patients exhibited new iodine uptake on diagnostic whole-body scans
After treatment with 5GBq of 88I at 3 months of follow-up, two patients had partial responses and four had stable disease
An ongoing trial is examining the effect of dabrafenib alone or in combination with a MEK inhibitor, trametinib:
In progressive, iodine-refractory, BRAF-mutated tumors (clinicaltrials.gov, NCT01723202)
TERT
Newly described in thyroid cancers, telomerase reverse transcriptase (TERT) promoter mutations:
Are found in low frequency in lower risk PTC (9%)
Increasing in frequency in more advanced PTC (51%):
PDTC (40%)
ATC (54% to 73%)
Telomerase is responsible for adding tandem repeats of the TTAAGGG sequence to the end of chromosomes:
To maintain genome stability
Whereas these enzymes are highly expressed in germline and stem cells, expression is reduced or even repressed in somatic cells
The loss of telomeres during somatic cell division:
Results in cells entering senescence
Reactivation of telomerase leads to immortalization:
By way of unrestricted proliferation and inactivation of replicative senescence
Although there are conflicting reports regarding the effect of a TERT mutation on prognosis in PTC:
A recent meta-analysis demonstrated that the presence of coexisting BRAF and TERT mutations was associated with a more aggressive clinical course and another study demonstrated higher mortality rates
Further study is needed to determine the feasibility of pharmacologic therapy targeting TERT mutations
Age at Diagnosis
Age at the time of tumor diagnosis is one of the most important contributing factors to prognosis:
There is a trend of worsening cause-specific survival for each decade starting at age 60 compared with younger patients (less than 20 years old)
An analysis of the NCDB revealed an incremental increase in 10-year mortality:
By 30% to 50% per 5 year increment beginning at age 35 years
A recent study determined that the age-associated increasing risk of mortality was associated with BRAF mutational status:
This multi-institutional study found that age is a strong, continuous, and independent mortality risk factor in patients with a BRAF V600E mutation but not in those with wild-type BRAF
Older patients are also more likely to harbor more aggressive histologic subtypes
In patients with distant metastases:
Those over the age of 40 years are less likely to demonstrate iodine avidity in their lung metastases
Children and adolescents:
Are more likely to have a more advanced tumor stage at the time of diagnosis
Up to 80% harbor nodal involvement and 15% to 20% develop pulmonary metastases rates that are nearly double those seen in adults
Despite the extent of disease at the time of diagnosis, children generally have excellent outcomes
In one systematic review of pediatric patients with pulmonary metastases, a complete response to radioactive iodine (RAI) therapy was seen in up to 50% and disease-specific mortality was 2.7%
NCCN Guidelines, Head and Neck Cancers (v2.2026) still base clinical staging definitions on AJCC 8th edition (ST-4 for p16-negative, ST-7 for p16-positive):
Version 9 is not yet incorporated
Version 9 changes apply only to:
HPV-positive (p16+) oropharyngeal carcinoma
The p16-negative oropharynx / hypopharynx system:
Is unchanged in the current NCCN tables
T – Tumor:
TX – Primary tumor cannot be assessed
Tis – Carcinoma in situ
T1 – Tumor 2 cm or smaller in greatest dimension
T2 – Tumor larger than 2 cm but not larger than 4 cm in greatest dimension
T3 – Tumor larger than 4 cm in greatest dimensión or extensión to lingual surface of epiglottis
T4 – Moderately advanced or very advanced local disease
T4a – Moderately advanced local disease
Tumor invades the larynx, extrinsic muscle of tongue, medial pterygoid muscle, hard palate, or mandible
T4b – Very advanced local disease
Tumor invades lateral pterygoid muscle, pterygoid plates, lateral nasopharynx, or skull base or encases carotid artery
Rodrigo Arrangoiz MS, MD, FACS, FSSO 